- Home
- LOT vs TARS Comparison
LOT vs TARS Comparison
Compare LOT & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOT
- TARS
- Stock Information
- Founded
- LOT 1948
- TARS 2016
- Country
- LOT China
- TARS United States
- Employees
- LOT N/A
- TARS N/A
- Industry
- LOT
- TARS Medicinal Chemicals and Botanical Products
- Sector
- LOT
- TARS Health Care
- Exchange
- LOT NYSE
- TARS Nasdaq
- Market Cap
- LOT 2.5B
- TARS 2.1B
- IPO Year
- LOT N/A
- TARS 2020
- Fundamental
- Price
- LOT $3.47
- TARS $46.52
- Analyst Decision
- LOT
- TARS Strong Buy
- Analyst Count
- LOT 0
- TARS 5
- Target Price
- LOT N/A
- TARS $54.20
- AVG Volume (30 Days)
- LOT 146.2K
- TARS 735.2K
- Earning Date
- LOT 11-21-2024
- TARS 02-25-2025
- Dividend Yield
- LOT N/A
- TARS N/A
- EPS Growth
- LOT N/A
- TARS N/A
- EPS
- LOT N/A
- TARS N/A
- Revenue
- LOT $1,013,890,000.00
- TARS $129,621,000.00
- Revenue This Year
- LOT $41.67
- TARS $917.88
- Revenue Next Year
- LOT $65.29
- TARS $78.70
- P/E Ratio
- LOT N/A
- TARS N/A
- Revenue Growth
- LOT 213.08
- TARS 801.96
- 52 Week Low
- LOT $3.05
- TARS $20.08
- 52 Week High
- LOT $17.99
- TARS $57.14
- Technical
- Relative Strength Index (RSI)
- LOT 44.54
- TARS 37.06
- Support Level
- LOT $3.05
- TARS $43.61
- Resistance Level
- LOT $4.09
- TARS $57.00
- Average True Range (ATR)
- LOT 0.36
- TARS 2.65
- MACD
- LOT -0.02
- TARS -1.27
- Stochastic Oscillator
- LOT 31.11
- TARS 21.51
About LOT LOTUS TECHNOLOGY INC
Lotus Technology Inc is a battery electric vehicle (BEV) maker that designs, develops, and sells BEV lifestyle vehicles under the Lotus brand. The Group is also a distributor that sells luxury sports cars under the Lotus brand. It also provides other sales and ancillary services to customers.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.